dicrofenac and travoprost

ApprovedSmall molecule

TTokyo University

dicrofenac and travoprost is one of 4 small molecule programs targeting Hyperemia. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HyperemiaActive, not recruiting

HyperemiaApproved

Active, not recruiting

Competition

Competitive Landscape

8 competitors in Hyperemia

#DrugCompanyPhaseTrials

dicrofenac and travoprost

TTokyo University

Approved

1 2

Adenocard

Astellas

Phase 1

1 3

Lexiscan

Astellas

Phase 1

1 4

Alphagan

AbbVie

Phase 1

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hyperemia1 trial

Effect of NSAID on Travoprost-induced Conjunctival Hyperemia and IOP Reduction in Normal Eyes

Completed·TTokyo University·Phase 4·NCT02136589·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for dicrofenac and travoprost. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — dicrofenac and travoprost compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for dicrofenac and travoprost. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Tokyo University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: TTokyo University

dicrofenac and travoprost

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Hyperemia1 trial

References

Drug Info

Quick Facts

Related News